Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix.

By Gonzalez-Barcena D   Alvarez R B   Ochoa E P   Cornejo I C   Comaru-Schally A M   Schally A V   Engel J   Reissmann T   Riethmüller-Winzen H  

Human Reproduction, Vol. 12, Iss. 9, 1997-09 ,pp. : 2028-2035

Oxford University Press

Access to resources Recommend Favorite

Prospective randomized study of an ultrashort gonadotrophin-releasing hormone agonist versus a modified suppression protocol for ovarian stimulation in intracytoplasmic sperm injection cycles.

By Strohmer H   Chatwani S   Wieser F   Danninger B   Obruca A   Feichtinger W  

Human Reproduction, Vol. 12, Iss. 7, 1997-07 ,pp. : 1403-1408

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. Effects of gonadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro— results of a prospective, randomized in-vitro fertilization study

By Dor J.   Bider D.   Shulman A.   Levron J.   Shine S.   Mashiach S.  

Human Reproduction, Vol. 15, Iss. 6, 2000-06 ,pp. : 1225-1230

Oxford University Press

Access to resources Recommend Favorite

Tailoring the GnRH antagonist cetrorelix acetate to individual patients’ needs in ovarian stimulation for IVF: results of a prospective, randomized study

By Ludwig M.  

Human Reproduction, Vol. 17, Iss. 11, 2002-11 ,pp. : 2842-2845

Oxford University Press

Access to resources Recommend Favorite

Effectiveness of a low gonadotrophin-releasing hormone antagonist dose in preventing premature luteinizing hormone rise during controlled ovarian stimulation

By Tiboni Gian Mario   Palumbo Paola   Leonzio Emiliana   Gabriele Elisabetta   Verna Ilde   Giampietro Franca  

Gynecological Endocrinology, Vol. 27, Iss. 11, 2011-11 ,pp. : 885-889

Informa Healthcare

Access to resources Recommend Favorite